

Anticoagulants Monitoring Table

Anticoagulant Comparison Table

Drug	Trade Name	Indications	Administration	Action	Monitoring
Argatroban	Acova, Novastan (in some countries) - mostly known as argatroban	For prophylaxis or treatment of thrombosis in adult patients with (HIT) • As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention	IV	Direct Thrombin Inhibitor (DTI)	ACT/aPTT. PT, INR, and TT are affected by argatroban, but therapeutic ranges have not been identified. In clinical trials in PCI, ACT was used for monitoring argatroban anticoagulant activity during the procedure. The concomitant use of argatroban and warfarin results in prolongation of the PT and INR beyond that produced by warfarin alone.
Bivalirudin	Angiomax	• Undergoing PCI with provisional use of GPIIb/IIIa inhibitor, • With, or at risk of, HIT and HITS undergoing PCI • With unstable angina undergoing PTCA. Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.	IV	Direct Thrombin Inhibitor (DTI)	ACT (patients with renal impairment)
Dabigatran	Pradaxa	Reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation • Treatment of DVT & PE in patients who have been treated with a parenteral anticoagulant for 5-10 days • Reduce risk of recurrence of DVT and PE in patients who have been previously treated.	Oral	Direct Thrombin Inhibitor (DTI)	Hemoclot Thrombin Inhibitor assay (currently RUO in US), or ECT - both better than aPTT. At recommended therapeutic doses, dabigatran etexilate prolongs the coagulation markers such as aPTT, ECT, and TT. The aPTT test provides an approximation of PRADAXA's anticoagulant effect.
Apixaban	Eliquis	reduce the risk of stroke and blood clots in people who have atrial fibrillation, treat and prevent DVT & PE, and to reduce the risk of DVT & PE in hip or knee replacement surgery.	Oral	FXa Inhibitor	aPTT/anti-Fxa when needed. Apixaban does not require routine laboratory monitoring in the majority of patients. Apixaban prolongs clotting tests such PT/INR, aPTT.
Enoxaparin (LMWH)	Lovenox	Prophylaxis of DVT in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness, inpatient treatment of acute DVT with or without PE, Outpatient treatment of acute DVT without PE, Prophylaxis of ischemic complications of unstable angina and non-Q-wave MI, Treatment of acute STEMI managed medically or with subsequent PCI.	IV	FXa Inhibitor	Anti-FXa. Routine coagulation tests like PT & aPTT are relatively insensitive measures of Lovenox activity and, therefore, unsuitable for monitoring. Anti-FXa may be used to monitor patients where needed, e.g. with significant renal impairment.
Fondaparinux	Arixtra	Prophylaxis of DVT in patients undergoing hip fracture surgery, including extended prophylaxis; in patients undergoing hip replacement surgery; in patients undergoing knee replacement surgery; in patients undergoing abdominal surgery who are at risk for thromboembolic complications. Treatment of Acute DVT when administered in conjunction with warfarin. Treatment of Acute PE when administered in conjunction with warfarin.	IV	FXa Inhibitor	Anti-FXa. Fondaparinux can be measured by anti-Xa assay using the appropriate calibrator (fondaparinux). The activity of fondaparinux sodium is expressed in mg and cannot be compared with activities of heparin or low molecular weight heparins.
Heparin (UFH)	N/A	For prophylaxis and treatment of DVT & PE, prevention of post-operative DVT & PE, and prevention of clotting in arterial and cardiac surgery.	IV	FXa Inhibitor	aPTT or anti-Fxa. Must be monitored.
Edoxaban	Savaysa	To reduce the risk of stroke and blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. To treat DVT and PE in patients who have already been treated with an anti-clotting drug administered by injection or infusion (parenterally), for five to ten days.	Oral	FXa Inhibitor	Not routinely required. The anticoagulant effect of SAVAYSA cannot be reliably monitored with standard laboratory testing.
Rivaroxaban	Xarelto	To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment of DVT & PE, reduction in the risk of recurrence of DVT and of PE, prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.	Oral	FXa Inhibitor	Anti-FXa preferable; PT using Neoplastin. Xarelto® does not require routine coagulation monitoring. The following coagulation tests are increased: PT, aPTT, INR. INR especially is not appropriate to measure activity of Xarelto®.
Warfarin	Coumadin	Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism and of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement • Reduction in the risk of death, recurrent MI, and thromboembolic events such as stroke or systemic embolization after MI.	Oral	Vitamin K antagonist	PT/INR, Chromogenic FX

Anticoagulant Products Comparison Table

Item Number	Description	Associated Kit	Research Use Only (RUO) or In Vitro Diagnostic Use (IVD)	Stability (After Recon)	Drug	Drug Trade Name
5090140	Technoview Argatroban Calibrator Set	TECHNOCLOT® DTI, 5100025	RUO	Not yet available	Argatroban	Acova, Novastan
5090142	Technoview Argatroban Control, High	TECHNOCLOT® DTI, 5100025	RUO	Not yet available	Argatroban	Acova, Novastan
5090144	Technoview Argatroban Control, Low	TECHNOCLOT® DTI, 5100025	RUO	Not yet available	Argatroban	Acova, Novastan
5090210	Technoview Dabigatran Calibrator Set	TECHNOCLOT® DTI, 5100025	RUO	RT: 8 hours; +2-8 °C: 24 hours; -20 °C: 1 month	Dabigatran	Pradaxa
5090212	Technoview Dabigatran Control, Low	TECHNOCLOT® DTI, 5100025	RUO	RT: 8 hours; +2-8 °C: 24 hours; -20 °C: 1 month	Dabigatran	Pradaxa
5090214	Technoview Dabigatran Control, High	TECHNOCLOT® DTI, 5100025	RUO	RT: 8 hours; +2-8 °C: 24 hours; -20 °C: 1 month	Dabigatran	Pradaxa
C823500	Chromogenix LMWH Calibration Plasma	Coamatic Heparin, K823393	IVD	RT: 24 hours; 2-8°C: 14 days	Low Molecular Weight Heparin	Lovenox
C82492	Chromogenix LMWH Control Plasma	Coamatic Heparin, K823393	IVD	RT: 24 hours; 2-8°C: 14 days	Low Molecular Weight Heparin	Lovenox
5090040	Technoview LMWH Calibrator Set	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Low Molecular Weight Heparin	Lovenox
5090041	Technoview LMWH Calibrator Kit	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Low Molecular Weight Heparin	Lovenox
5090042	Technoview LMWH Control, Low	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Low Molecular Weight Heparin	Lovenox
5090044	Technoview LMWH Control, Medium	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Low Molecular Weight Heparin	Lovenox
5090046	Technoview LMWH Control, High	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Low Molecular Weight Heparin	Lovenox
5090269	Technoview Apixaban Calibrator Set	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Apixaban	Eliquis
5090270	Technoview Apixaban Control, Low	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Apixaban	Eliquis
5090271	Technoview Apixaban Control, High	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Apixaban	Eliquis
5090010	Technoview Arixtra Calibrator Set	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Fondaparinux	Arixtra
5090012	Technoview Arixtra Control, Low	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Fondaparinux	Arixtra
5090014	Technoview Arixtra Control, High	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Fondaparinux	Arixtra
5090170	Technoview Rivaroxaban Calibrator Set	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Rivaroxaban	Xarelto
5090171	Technoview Rivaroxaban Calibration Kit	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Rivaroxaban	Xarelto
5090172	Technoview Rivaroxaban Control, Low	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Rivaroxaban	Xarelto
5090173	Technoview Rivaroxaban Control, Medium	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Rivaroxaban	Xarelto
5090174	Technoview Rivaroxaban Control, High	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days	Rivaroxaban	Xarelto
5090070	Technoview UFH Calibrator	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Unfractionated Heparin	(UFH)
5090071	Technoview UFH Calibration Kit	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Unfractionated Heparin	(UFH)
5090072	Technoview UFH Control, Low	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Unfractionated Heparin	(UFH)
5090074	Technoview UFH Control, High	Technochrom anti-Xa, 5340250	RUO	RT: 48 hours; +2-8 °C: 7 days; -20 °C: 1 month	Unfractionated Heparin	(UFH)
5010004	AK-Calibrant	N/A	RUO	RT: 4 hours; +2-8 °C: 8 hours; -20 °C: 1 month	Warfarin	Coumadin
5011050	Coag Control AK (5x1 mL)	N/A	RUO	RT: 4 hours; +2-8 °C: 8 hours; -20 °C: 1 month	Warfarin	Coumadin
5011060	Coag Control AK (50x1 mL)	N/A	RUO	RT: 4 hours; +2-8 °C: 8 hours; -20 °C: 1 month	Warfarin	Coumadin
N/A	N/A	N/A	N/A	N/A	Edoxaban	Savaysa



www.diapharma.com
1.800.526.5224